Drugs newsletters promo codes, discounts and updates

Drugs

Drugs

Add to my subscriptions

FDA Safety Alert: Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare Delivery System

July 1, 2024

The Offer: Learn how the FDA's Risk Evaluation and Mitigation Strategies are shaping the future of CAR T cell immunotherapies for improved patient safety and healthcare delivery.

Summary: Stay informed on the recent modifications to the Risk Evaluation and Mitigation Strategies (REMS) affecting Autologous Chimeric Antigen Receptor (CAR) T cell immunotherapies. This safety initiative from the FDA addresses serious concerns like cytokine release syndrome (CRS) and neurological toxicities. Learn more about the restricted program that includes popular therapies like Abecma, Breyanzi, Kymriah, and Yescarta, ensuring a balance between therapy benefits and risks. Keep pace with the evolving landscape of CAR T cell treatments and how they are reshaping healthcare delivery systems. Click below for further details!